Top 5 Drug Type | Count |
---|---|
Small molecule drug | 34 |
Biosimilar | 7 |
Unknown | 6 |
Monoclonal antibody | 4 |
Colony-stimulating factors | 3 |
Target |
Mechanism adrenergic receptor agonists |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date14 Jun 2021 |
Target- |
Mechanism Glycolysis inhibitors [+1] |
Active Org. ![]() |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 May 2021 |
Target |
Mechanism 5-HT1A receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. GB |
First Approval Date20 Sep 2018 |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date29 Mar 2024 |
Sponsor / Collaborator |
Start Date29 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Rituximab biosimilar(Dr. Reddy's Laboratories) ( CD20 ) | Rheumatoid Arthritis More | Approved |
Bevacizumab biosimilar(Dr. Reddy's Laboratories) ( VEGF-A ) | Fallopian Tube Carcinoma More | Approved |
Norethindrone/Ethinyl Estradiol ( ER x PR ) | Contraception More | Approved |
Cyclophosphamide ( DNA ) | Burkitt Lymphoma More | Approved |
2-Deoxyglucose | COVID-19 More | Approved |